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Abstract: The toxic moiety of almost all protein-based targeted toxins must enter the cytosol of the
target cell to mediate its fatal effect. Although more than 500 targeted toxins have been investigated
in the past decades, no antibody-targeted protein toxin has been approved for tumor therapeutic
applications by the authorities to date. Missing efficacy can be attributed in many cases to insufficient
endosomal escape and therefore subsequent lysosomal degradation of the endocytosed toxins. To
overcome this drawback, many strategies have been described to weaken the membrane integrity
of endosomes. This comprises the use of lysosomotropic amines, carboxylic ionophores, calcium
channel antagonists, various cell-penetrating peptides of viral, bacterial, plant, animal, human and
synthetic origin, other organic molecules and light-induced techniques. Although the efficacy of the
targeted toxins was typically augmented in cell culture hundred or thousand fold, in exceptional
cases more than million fold, the combination of several substances harbors new problems including
additional side effects, loss of target specificity, difficulties to determine the therapeutic window
and cell type-dependent variations. This review critically scrutinizes the chances and challenges of
endosomal escape enhancers and their potential role in future developments.
Keywords: endosomal escape; efficacy enhancers; targeted toxins; immunotoxins; cytosolic drug
delivery; controlled drug release; cancer treatment; endocytosis
1. Introduction
Targeted protein toxins represent one of the high hopes for future drugs in the fight against cancer.
They consist of a targeting domain chemically coupled or recombinantly fused to a toxic payload for
tumor cell killing [1]. In most of the cases, the targeting moiety is an antibody-based domain including
various forms of full regular antibodies, single chain antibodies, bivalent or bispecific diabodies and
minibodies [2–5], and this type of targeted toxins is therefore called immunotoxins. The diversity
of these molecules allows the selection of very specific structures for the targeting of tumor cells,
however, the protein toxins take their effect inside the cytosol. Therefore, targeting of the toxin to
the cell surface is a prerequisite for specificity but not sufficient for efficacy. In many constellations,
the toxin remains ineffective since: (1) the antibody is poorly internalized and remains bound to the
outside of the cells; (2) is recycled back to the cell surface after internalization; or (3) transported to
the lysosomes where it is degraded [6–8]. Although these fundamental issues are known for decades,
the problems have not been solved yet and no antibody-targeted protein toxin has been approved
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for tumor therapeutic applications by the authorities to date. It is obvious that a major problem is
the endosomal escape within sufficient time. To overcome this drawback, many strategies have been
described including approaches to redirect the toxins to endogenous cellular membrane transport
complexes of the biosynthetic pathway in the endoplasmic reticulum, disrupting the endosomes,
weaken the membrane integrity of endosomal membranes or diving through these membranes with
the assistance of cell penetrating peptides [9–12].
All strategies including physicochemical techniques require molecules that interact more or less
directly with membranes and comprise essentially small chemical molecules, secondary metabolites,
peptides and proteins. A common feature of all these substances is that they are per se not target-specific
and distribute with other kinetics than the targeted toxins. Therefore, a number of requirements can be
formulated for endosomal escape enhancers: (1) they must not be toxic for regular cells; (2) they must
not mediate the cytosolic uptake of the targeted toxin into off-target cells; (3) their presence at the site
of action must by synchronized with the presence of the targeted toxin; (4) they must be biodegradable
or excretable; and (5) they must not substantially interfere with metabolic processes of the organism,
e.g., interact with hormones. It is easy to recognize that most of these criteria can only be sufficiently
tested in in vivo systems, however, most of the published endosomal escape enhancers have only
be tested in vitro, which may explain the lack of success of these strategies in clinical applications.
The present review describes the different approaches to augment the efficacy of targeted toxins by
endosomal escape enhancers including chemical, viral, bacterial and eukaryotic substances. It then
discusses the pros and cons of the different techniques with regard to the mentioned requirements and
weighs the prospects and risks for future clinical development of the different strategies.
2. Chemical Enhancers
Many different chemical enhancers have been described in the literature to augment the efficacy
of targeted toxins. These compounds are generally small chemical molecules with great variability that
increase in some way or another the cytotoxicity of targeted toxins. Within the chemical enhancers, the
compounds can be classified in several subgroups depending on their chemical nature and molecular
mechanism. This includes the subgroups of lysosomotropic amines, carboxylic ionophores, calcium
channel antagonists, and other organic compounds. Detailed information is provided for each of the
subgroups in the following subsections.
2.1. Lysosomotropic Amines
When cells are treated with targeted toxins, they are commonly internalized into cells by
receptor-mediated endocytosis and then undergo their intracellular routing. A substantial amount of
targeted toxins are not able to reach their intracellular target and accumulate in the lysosomes where
they are degraded. This is one of the main limitations of targeted toxins and results in the decrease
of their efficacy [13]. Lysosomotropic amines increase the lysosomal pH and therefore interrupt the
degradation of proteins by pH-dependent lysosomal enzymes [14]. Since they have their site of action
inside the lysosomes, only targeted toxins that mainly accumulate in these organelles are likely to
be enhanced. A list of the lysosomotropic amines that have been reported to facilitate the cytosolic
delivery of targeted toxins is presented in Table 1.
Ammonium chloride was firstly used to enhance the cytotoxicity of an anti-melanotransferrin-ricin
A chain immunotoxin [15]. The cytotoxic effects were enhanced roughly 100-fold and this encouraged
the investigation about combinatorial effects of ammonium chloride with further targeted toxins. The
most prominent effects were observed in the case of targeted toxins based on ricin toxin A chain (RTA).
As an example, the cytotoxicity of three RTA immunotoxins directed to the cell surface antigens Thy
1.2 (cluster of differentiation 90, CD90), melanotransferrin and CD5 was augmented by 5.7, 42 and
6700 folds, respectively [16]. On the contrary, the cytotoxicity of diphtheria toxin was blocked when
it was administered to cells in the presence of ammonium chloride [17], which was not surprising
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since it has been known that inhibition of the vacuolar-type H(+)-ATPase also blocked diphtheria toxin
toxicity [18].
Chloroquine is another lysosomotropic amine that has been extensively studied. The highest
enhancing effects were again observed in the case of targeted toxins containing RTA. The immunotoxin
T101-RTA was enhanced 2500-fold by chloroquine [16]. Chloroquine was also efficient in enhancing
the cytotoxic effects of targeted toxins composed of gelonin [19], pokeweed antiviral protein [20] and
saporin [21], although the enhancing effects were moderate.
Other lysosomotropic amines that are able to enhance the efficacy are amantadine [22],
methylamine, dimethylamine, trimethylamine [16], lipopolyamines [23], quinacrine (mepacrine) [19]
and glycylphenylalanine 2-naphthylamide [24]. All compounds were simultaneously co-administered
with the targeted toxins and are believed to act in the same way as proton reservoirs through their
amine groups thus preventing the acidification of the lysosomes.
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Table 1. Ammonium chloride and lysosomotropic amines that enhance the cytotoxicity of targeted toxins. All listed substances act by increasing the pH in the
lysosomes and thus preventing degradation.




ricin A chain CD5 T101-RTA 1 mM 1180 [16]
saporin
CD5 OKT1-SAP 1 mM 4 [25]
CD5 T101-SAP 1 mM 4 [25]
CD5 SOT1a-SAP 1 mM 4 [26]
Ammonium chloride ricin A chain
CD5 T101-RTA 10 mM 6700 [16]
Thy 1.2 (CD 90) AT15E-RTA 10 mM 6 [16]
melanotransferrin 96.5-RTA 10 mM 42 [16]
CD7 WT1-RTA 6 mM 100 [27]
CD25 anti-TAC-RTA 10 mM 100 [28]
cCLLa CLL2m/RTA 10 mM 80 [29]
EGFR EGF-RTA 10 mM 12 [30]
CD3 WT32-RTA 6 mM Significant increase [31]
Chloroquine
gelonin LH receptor lutropin-gelonin 9.6–29 µM 15 [19]
GD2 gelonin-14G2a 10 µM 10 [32]
pokeweed antiviral protein
transferrin receptor 5E9-11-PAP 10–100 µM 65 [20]
T cells T3-3A1-PAP 10–100 µM 65 [20]
CD19 B43-PAP 40 µM Significant increase [33]
ricin A chain CD5 T101-RTA 100 µM 2500 [16]
saporin transferrin receptor saporin-transferrin 10 µM Significant increase [21]
granzyme B EGFR Gb(R201K)-scFv1711 50 µM 3 [34]
Dimethylamine ricin A chain CD5 T101-RTA 10 mM 3300 [16]
Lipopolyamines saporin urokinase receptor uPA-saporin 5 µg/mL 83 [23]
Methylamine ricin A chain CD5 T101-RTA 10 mM 13,300 [16]
Quinacrine gelonin LH receptor lutropin-gelonin 2.6–7.6 µM 15 [19]
Trimethylamine ricin A chain CD5 T101-RTA 10 mM 80 [16]
β-Glycylphenyl-naphthylamide (GPN) Pseudomonas exotoxin
transferrin receptor HB21-PE 10–20 µg/mL 9 [24]
EGFR EGF-PE 10–20 µg/mL 6 [24]
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2.2. Carboxylic Ionophores
Carboxylic ionophores have been successful in enhancing the delivery of targeted toxins to the
cytosol. Carboxylic ionophores integrate in lipid bilayers and mediate the exchange of monovalent
cations across the membranes. An example of this mechanism is the exchange of sodium ions and
protons by monensin [35]. When administered to cells, carboxylic ionophores increase the lysosomal
pH and this finally results in blocking protein degradation inside the lysosomes [36]. At the same
time, the inhibition of lysosomal degradation may augment the cytotoxic effects of targeted toxins as
observed for lysosomotropic amines. A list of such carboxylic ionophores is available in Table 2.
Monensin is the most well studied compound within the carboxylic ionophores. The highest
enhancement effects were observed in the case of targeted toxins comprising ricin A chain.
The cytotoxicity of the immunotoxin T101-RTA was augmented 50,000 folds in the presence of
monensin [16]. In another example, an immunotoxin recognizing the neural cell adhesion molecule
(SEN36-RTA) was enhanced by 12,000-fold when co-applied with monensin [37]. As a third example,
the amount of 3A1-rRTA immunotoxin required to inhibit protein synthesis by 50% was decreased
by 1000 folds [38]. Monensin also augmented the cytotoxic effects of a targeted toxin consisting of
transferrin and saporin by 1250-fold [39], and more moderately of two gelonin-based targeted toxins
directed to the gonadotropin receptor [19] and the disialoganglioside GD2 [32].
On the other hand, the use of monensin in vivo is hindered by poor solubility and a short
half-life [40]. In order to overcome these limitations, monensin was conjugated to human serum
albumin [41]. Alternatively, monensin was delivered in lipid emulsions [42], encapsulated in
liposomes [43] or in poly(lactic-co-glycolic acid) (PLGA) polymer nanoparticles [44]. These strategies
that were all conducted in conjunction with ricin A chain-based targeted toxins managed to augment
the solubility and to prolong the half-life of the chemical enhancer.
Other carboxylic ionophores that have potentiated the cytotoxic effects of targeted toxins are
grisorixin, lasalocid and nigericin. These three compounds enhanced the T101-RTA immunotoxin by
25,000; 33,000 and 6700 folds, respectively [16]. Significant increase in cytotoxicity was observed as
well for the combination of nigericin with transferrin-RTA, anti-common acute lymphoblastic leukemia
antigen (CALLA, CD10)-RTA [45] and anti-carcinoembryonic antigen (CEA)-RTA [46] targeted toxins.
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Table 2. Carboxylic ionophores that enhance the cytosolic uptake of targeted toxins. The compounds in the list presumably take effect by augmenting the pH in the
lysosomes and blocking the lysosomal degradation of targeted toxins.
Enhancer Toxin Antigenic Target Targeted Toxin Enhancer Concentration Max. Enhancement Factor Ref.
Grisorixin ricin A chain CD5 T101-RTA 50 nM 25,000 [16]
Lasalocid ricin A chain CD5 T101-RTA 1 µM 33,000 [16]
Monensin
gelonin LH receptor lutropin-gelonin 0.3–2.9 µM 15 [19]
GD2 gelonin-14G2a 100 nM 10 [32]
ricin A chain
CD5 T101-RTA 50 nM 50,000 [16]
Thy 1.2 AT15E-RTA 50 nM 4 [16]
p97 96.5-RTA 50 nM 420 [16]
transferrin receptor Tfn-RTA 10–100 nM 30,000 [45]
CD10 anti-CALLA-RTA 10–100 nM Significant increase [45]
CD25 anti-TAC-RTA 25 nM 400 [28]
CEA anti-CEA-RTA 0.5–1 µM Significant increase [46]
p55 260F9-rRTA 100 nM 34 [47]
gp74 45-2D9-RTA 0.5 µM Significant increase [48]
p55 260F9-rRTA 10–100 nM Significant increase [38]
CD7 3A1-rRTA 10–100 nM Significant increase [38]
transferrin receptor R17-217-rRTA 10–100 nM Significant increase [38]
transferrin receptor Tfn-RTA 900 nM 500 [39]
transferrin receptor OKT9-RTA 900 nM 3300 [39]
transferrin receptor OX26-RTA 900 nM 330 [39]
N-CAM SEN36-RTA 100 nM 12,000 [37]
MUC1 BrE-3-RTA 100 nM 100 [49]
transferrin receptor 454A12MAb-RTA 10–100 nM 4 [50]
saporin transferrin receptor Tfn-So6 900 nM 1250 [39]
Nigericin ricin A chain
CD5 T101-RTA 10 nM 6700 [16]
transferrin receptor Tfn-RTA 10–100 nM Significant increase [45]
CD10 anti-CALLA-RTA 10–100 nM Significant increase [45]
CEA anti-CEA-RTA 0.5 µM Significant increase [46]
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2.3. Calcium Channel Antagonists
Another group of chemicals that were able to enhance the cytotoxic effect of targeted toxins are
the calcium channel antagonists (Table 3). Verapamil was first identified as a cytotoxicity enhancer for
two Pseudomonas exotoxin (PE)-based toxins targeted to the epidermal growth factor (EGF) receptor
and the transferrin receptor [51]. Verapamil was also reported to enhance targeted toxins based on ricin
A chain [52] and gelonin [19]. In order to find compounds with less in vivo toxicity, four verapamil
analogs (D792; D595; D528; Sz45) were investigated. These compounds were able to enhance the
cytotoxicity of targeted toxins in the range of 2´67 folds [53].
Further calcium channel antagonists that showed cytotoxicity enhancement of targeted toxins
are diltiazem and methoxyverapamil, both presenting combinatorial effects with the targeted toxins
HB21-PE and EGF-PE [24]. Two indolizines (SR 33287 and SR 33557) potentiated the cytotoxic effects
of the anti-CD5 T101-RTA immunotoxin by 620-fold [54]. The highest enhancing effects within this
group of compounds were observed in the case of perhexiline that increased the cytotoxicity of
two ricin A chain immunotoxins directed against CD5 and HLA-DR class II antigens present in
leukemia cells up to 2000 folds [55].
The enhancing ability of calcium channel antagonists is probably associated to the inhibition of
lysosomal degradation of targeted toxins and actually does not correlate with the calcium-antagonistic
activity [53]. Verapamil delays degradation in lysosomes and this could result in enhanced
toxicity, alternatively it may increase the therapeutic potential of targeted toxins by some general
effects on membrane permeability [51]. In the cases of perhexiline and indolizines, the delay of
protein degradation may occur as a consequence of the fact that they inhibit the acid lysosomal
sphingomyelinase [54]. This leads to changes in the membrane lipid composition of intracellular
organelles, supposedly modulates the intracellular routing of targeted toxins and facilitates their
delivery to the cytosol [55].
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Table 3. Calcium channel antagonists enhancing the cytotoxicity of targeted toxins. These substances probably cause their effect by blocking the lysosomal degradation
of targeted toxins and modulating their intracellular trafficking.
Enhancer Toxin Antigenic Target Targeted Toxin Enhancer Concentration Max. Enhancement Factor Ref.
Diltiazem Pseudomonas exotoxin
transferrin receptor HB21-PE 10–20 µg/mL 6 [24]
EGFR EGF-PE 10–20 µg/mL 8 [24]
Indolizine (SR 33287; SR33557) ricin A chain
CD5 T101-RTA 5 µM 620 [54]
Thy 1.2 AT15E-RTA 5 µM 84 [54]
Methoxyverapamil (D-600) Pseudomonas exotoxin
transferrin receptor HB21-PE 5–20 µg/mL 12 [24]
EGFR EGF-PE 5–20 µg/mL 20 [24]
Perhexiline ricin A chain
CD5 T101-RTA 1–5 µM 2000 [55]
HLA-DR class II HNC-241-RTA 1–10 µM 100 [55]
Verapamil
gelonin LH receptor lutropin-gelonin 10–41 µM 15 [19]
Pseudomonas exotoxin
transferrin receptor HB21-PE 2.5–20 µg/mL 11 [24]
EGFR EGF-PE 10–20 µg/mL 40 [24]
ricin A chain
transferrin receptor 454A12-rRTA 20 µg/mL 25 [52]
p55 260F9-rRTA 20 µg/mL 8 [52]
HER2 454C11-RTA 20 µg/mL Significant increase [52]
cCLLa CLL2m/RTA 20 µg/mL 80 [29]
Verapamil analogs (D792; D595; D528; Sz45)
Pseudomonas exotoxin transferrin receptor HB21-PE 20 µM 35 [53]
ricin A chain
transferrin receptor 454A12-rRTA 1–20 µg/mL 67 [53]
p55 260F9-rRTA 20 µM Significant increase [53]
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2.4. Other Organic Compounds
Other organic compounds that do not fit into the classification defined in the previous subsections
have been also reported to enhance the cytotoxicity of targeted toxins. A list of these compounds
is shown in Table 4. Retinoic acid enhanced the cytotoxicity of several targeted toxins comprising
ricin A chain but failed to deliver diphtheria toxin and Pseudomonas exotoxin to the cytosol [56]. The
mechanism of action of retinoic acid may be associated to the modulation of the intracellular trafficking
of targeted toxins into the Golgi apparatus.
Further organic compounds have shown significant increase in the cytotoxicity of targeted toxins,
however, their mechanism of action is not completely clear and different hypothesis have been
formulated for each of the compounds. Brefeldin-A enhanced two ricin A chain immunotoxins
and is believed to have its effect on the Golgi apparatus and on the vesicular routing [57]. The
combination of Pseudomonas exotoxin-based immunotoxins with cyclosporin A caused remarkable
synergistic cytotoxicity in several cancer cell lines, although the combinatorial effect was not linked to
the immunosuppressive activity [58]. Similarly, wortmannin enhanced the cytotoxicity of saporin- and
gelonin-based targeted toxins, but the effect may occur through an alternative pathway not involving
the phosphatidylinositol-3-kinase inhibition [59].
Organic polymers comprise a big variety of compounds that has been investigated mainly for gene
delivery [60]. Amongst this group of compounds, there is one, namely polyamidoamine, that has been
considered for the enhanced cytosolic delivery of non-targeted toxins [61,62]. Further investigation of
polyamidoamine effects in the context of targeted toxins would be of interest.
Table 4. Other organic compounds that enhance the cytotoxicity of targeted toxins. Listed substances
induce their effect on different intracellular vesicular compartments. For some of the compounds, the








Brefeldin-A ricin A chain
transferrin
receptor 454A12-rRTA 0.05–0.5 µg/mL Significant increase [57]




EGFR 425.3PE 2 µM Significant increase [58]
MUC1 BM7PE 2–4 µM 40 [58]
EpCAM (EGP-2) MOC31PE 2 µM Significant increase [58]
ricin A chain
gp70 2F10-RTA 25 mg/kg (in vivo) 100 [63]
CD5 T101-RTA 4 µmol/mL 101 [64]
Cyclosporin
SDZ PSC 833 ricin A chain CD5 T101-RTA 4 µmol/mL 105 [64]
Retinoic acid ricin A chain
transferrin
receptor 454A12-rRTA 10 µM 10,000 [56]
transferrin
receptor Tfn-rRTA 10 µM 1000 [56]
B cells M6-rRTA 10 µM Significant increase [56]
p55 260F9-rRTA 10 µM Significant increase [56]
Wortmannin
gelonin bFGFR bFGF-gelonin 1–10 µM Significant increase [59]
saporin
bFGFR bFGF-SAP 1–10 µM Significant increase [59]
EGFR HBEGF-SAP 1–10 µM Significant increase [59]
bFGFR 11A8-SAP 1–10 µM Significant increase [59]
3. Enhancers of Viral and Bacterial Origin
Viruses have deployed effective intrinsic mechanisms in order to enter the cytosol of their host cells.
Viruses are able to fuse directly with cellular membranes resulting in the cytosolic release of the viral
particles but they are also internalized via endocytosis [65]. In case they are internalized by endocytosis,
they are delivered into early or late endosomes. To exploit the cellular protein machinery, the viruses
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need to escape from the endosomes, a process that is mediated by specific viral fusion proteins [66] and
cell-penetrating peptides (CPPs). Cell penetrating peptides, also termed protein-transduction domains,
are widely used as tool to mediate the cytosolic delivery of proteins and other molecules [67,68].
One of the most prominent CPPs is the transactivating factor of the human immunodeficiency virus
(HIV) [69]. There are many known different cell penetrating peptides [70]. They are frequently
composed of cationic amino acids such as arginine and lysine. CPPs are widely used to augment the
endosomal escape of protein therapeutics, e.g., CPPs derived from viruses have been used to deliver
different proteins such as green fluorescent protein (GFP), insulin or β-galactosidase into the cytosol of
cells [71,72]. As a general delivery platform, a fusion protein of the HIV transactivator of transcription
(Tat) and calmodulin was designed in order to drag different calmodulin binding proteins into the
cytosol of eukaryotic cells [73]. However a drawback of this approach is the non-specific delivery of
protein cargo into off-target cells. Due to their small size of only several amino acids, the sequence of
a CPP can be easily integrated into the sequence of targeted, recombinant anti-tumor toxins, which
resulted in a targeted CPP. By inserting cleavage sites CPPs can be cleaved off after cytosolic delivery
of the protein cargo. One example is the construction of a targeted anti-tumor toxin consisting of
human EGF, a CCP from the hepatitis B virus and an endosomal cleavable peptide [74]. The fusion of
viral CPPs to ribosome-inactivating proteins improved significantly the efficacy of these toxins against
cancer cells [75–77]. The products are therefore optimized targeted anti-tumor toxins with fusogenic
properties (Table 5).
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Table 5. Viruses and virus peptides showing enhancement effects on the cytotoxicity of targeted toxins. It is expected that the mechanism is similar to the natural
process of fusogenic peptides of viral origin when viruses enter the cytosol of infected cells.
Enhancer Application Toxin Antigenic Target Targeted Toxin Enhancer Concentration Max. Enhancement Factor Ref.
Adenovirus whole virus
Pseudomonas exotoxin EGFR PE-EGF 2 ˆ 109 pfu/mL 10,000 [78]
ricin A chain CEA anti-CEA-RTA 3 ˆ 108 pfu/mL 33 [46]
Penton base protein
(adenovirus capsid protein) whole virus Pseudomonas exotoxin EGFR PE-EGF 9 ˆ 10
3 viruses/cell Significant increase [79]
KFT25
(N-terminus of Protein G)
viral peptides
(fusion proteins)
dianthin transferrin receptor Tfn-KFT25-DIA ď30,000 ng/mL 3.8 [80]
ricin A chain transferrin receptor Tfn-KFT25-RTA ď10 pM 20 [81]
HA23 viral peptides(conjugates and free peptides) ricin A chain gp120 anti-gp120(HIV)-RTA-HA23 0–300 µg/ mL 5 [82]
PreS2-domain of hepatitis-B
virus surface antigen (TLM)
viral peptides
(fusion protein)
saporin EGFR saporin-TLM-EGF ď100 nM 1 (in vitro) 2.2 (in vivo) [74,83]
angiogenin CD64 anti-CD64-TLM-angiogenin ď100 nM 20 [84]
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Bacterial toxins are widely used as toxin components of targeted toxins. The most often used
bacterial toxins for the design of targeted toxins are truncated versions of Pseudomonas exotoxin A
(PE) [85]. PE comprises three domains, a receptor binding domain (Ia), a membrane translocation
domain (II) and the ADP-ribosyl transferase domain (Ib and III) [86]. The truncated domain II
mediates the translocation of domain Ia and III into the cytosol via the ER-associated degradation
pathway [87]. The specific domains of PE were optimized by evolution in order to facilitate the
efficient intracellular delivery of the ADP-ribosyl transferase domain into the cytosol [87,88]. For
the design and efficient delivery of targeted toxins, it might be therefore obvious to make use of
evolutionarily optimized transduction mechanisms rather than integrating artificial transduction
domains into targeted toxins such as CPPs. For instance, it has been shown for diphtheria toxin
from Corynebacterium diphtheria that the native diphtheria transduction domain (amino acids 190–390)
exhibited the highest cytotoxicity in a human EGF receptor-targeted anti-tumor toxin. Fusions between
several viral protein transduction domains and diphtheria toxin A chain were less cytotoxic in target
cells expressing the human EGF receptor [89]. It is therefore not surprising that a large number of
targeted toxins are based on Pseudomonas exotoxin A and diphtheria toxin [90–101]. A fusion protein
of interleukin-2 and a truncated diphtheria toxin consisting of 389 amino acids called DAB(389)IL-2
was the first and to date sole targeted protein toxin that has been approved by the U.S. Food and Drug
Administration under the name denileukin diftitox (Ontak®) [102]. A ten amino acids long motif in
the transmembrane helix 1 of diphtheria toxin that is conserved in anthrax (see next paragraph) and
botulinum neurotoxin serotypes mediates the delivery of the toxic domain from the lumen of early
endosomes to the cytosol [103]. Using DAB(389)IL-2 it has been demonstrated that introduction of
a L221E mutation into a highly conserved residue within this motif results in a nontoxic phenotype
that is unable to mediate cytosolic translocation [103]. Thus, this domain acts as an effective endosomal
escape enhancer.
A further intriguing approach to augment the endosomal escape process of targeted toxins is the
utilization of the protective antigen of Bacillus anthracis. This bacterium produces a lethal toxin (anthrax
toxin) that is composed of three domains: the lethal factor (LF), edema factor (EF) and protective antigen
(PA). LF is a toxic zinc protease and EF an adenylate cyclase that elevates intracellular cAMP levels. PA
mediates the endosomal escape by forming an acid induced pore in the endosomal membrane [104].
PA is activated by cellular furins on the cell surface. Since the PA-mediated delivery of LF and EF
is a highly efficient process, attempts have been made to utilize this mechanism for targeted tumor
therapies. By replacing the native furin cleavage site by tumor-specific cleavage sites, the PA-mediated
endosomal escape process can be utilized for the delivery of ADP-ribosyl transferases [105,106]. The
PA-mediated delivery has been also deployed for the target specific delivery of DNases such as the
cytolethal distending toxin [107] into tumor cells [108]. However, although the results of these studies
are promising, the strategies with modified anthrax toxins are afflicted with non-specific activation by
regular cells resulting in elevated side effects.
In addition to the use of specific bacterial protein transduction domains, integral attempts have
been made to co-deliver protein based cytolysins into the lysosomes of the cancer cells that have been
loaded with targeted toxins. Known cytolysins are streptolysin O from Streptococcus pyogenes [109],
perfringolysin O from Chlostridium perfringes [110] and listeriolysin O from Listeria monocytogenes [111].
In general, cytolysins are able to induce pore formation in lipid bilayers resulting in the leakage
of membranes. By fusing a targeting ligand (human fibronectin domain) to listeriolysin O,
a receptor-specific uptake of this construct into lysosomes was achieved [112]. This was also
observed for liposomal listeriolysin O that was co-encapsulated with the type I ribosome-inactivating
protein (RIP) gelonin [113]. The co-delivery of enhancers and targeted anti-tumor toxins resulted in
an augmented cytosolic release of the anti-tumor toxin and increased efficacy; however, a disadvantage
of this strategy is the potential immunogenicity of the enhancer. Although it is advantageous to recruit
immune effector cells to the tumor site, it is a drawback when the immune response is directed against
the enhancer or toxins themselves, which can, in worst case, result in anaphylactic shock.
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Viral and bacterial enhancers for the endosomal escape of targeted toxins revealed great potential
for the efficient cytosolic transfer. These enhancers are mostly based on particular protein domains that
were optimized by evolution. As targeted toxins are protein-based therapeutics, it is straightforward
to utilize viral or bacterial derived enhancer domains in recombinant fusion proteins. This is
advantageous since the targeting ligand, the effector molecule (toxin) and the delivery mechanism can
be integrated into a single clearly defined therapeutic compound.
4. Enhancers of Eukaryotic Origin
4.1. Proteins and Peptides
The enhancers of eukaryotic origin mainly comprise CPPs and pore forming proteins. Currently,
hundreds of CPPs have been found and used in biomedical research. CPPs are derived from various
proteins including transactivators of gene transcription, DNA/RNA-binding proteins, antimicrobial
peptides, viral particle envelope proteins and plant circular skeletal proteins [12]. CPPs of viral origin
have already been described before in this review. The most applied CPP of eukaryotic origin is
penetratin, a 16-amino acid long polypeptide corresponding to the third helix of the DNA binding
domain (homeodomain) of Antennapedia, a Drosophila transcription factor [114]. The peptide exists
in its natural form, in modified forms [115] or as synthetic analogs [116]. It has been widely used for
the cytosolic delivery of nucleic acids and proteins but was mainly ignored for targeted toxins [117].
Since the internalization of penetratin is receptor-independent [114] (as typical for all CPPs), it might
be difficult to erase this unwanted property in targeted toxins although successfully shown for the
PreS2-domain of hepatitis-B virus surface antigen [83,84]. Time will tell us whether CPPs have a future
in the delivery of targeted toxins.
A completely different approach is the use of pore forming proteins. Perforins are cytolytic
proteins found in the granules of cytotoxic T lymphocytes and natural killer cells that share homology
with cholesterol-dependent cytolysins from Gram-positive bacteria [118]. They rather circumvent the
endosomal escape instead of enhancing it. Since these proteins form pores, they cannot only be used to
bring toxic proteins into the cell but are also toxic by themselves. A recombinant immunotoxin
consisting of a fragment containing the N-terminal 34 amino acids of human perforin and the
C-terminus of a humanized anti-cytotoxic T-lymphocyte-associated protein (CTLA-4, CD152) scFv
antibody selectively depleted activated T cells to prevent transplant rejection [119].
Granzymes are potent apoptosis inducing serine proteases of cytotoxic lymphocytes. Following
receptor-mediated endocytosis, perforins mediate the cytosolic uptake of granzymes. A targeted toxin
consisting of vascular endothelial growth factor and mutated staphylococcal enterotoxin A was used
to attract cytotoxic T lymphocytes, which then secreted perforin and granzyme B (abbreviated as
GzmB, Gb or GrB) around the tumor resulting in granzyme B-mediated death of tumor cells supported
by perforins [120]. Although reliant on perforins in natural attacks, granzyme B can also effectively
kill tumor cells in the absence of perforin when targeted to cell surface receptors [121]. A number
of research groups took advantage of this phenomenon (Table 6). Granzyme B genetically fused to
H22, a humanized scFv specific for CD64, led to a target cell-specific cytotoxicity with a half-maximal
inhibitory concentration (IC50) between 1.7 and 17 nM [122]. A similar cytotoxicity (IC50 between 1.2
and 6.4 nM) was achieved when using granzyme M, however, target cells were killed efficiently even
in the presence of the granzyme B inhibitor serpin B9 that is often expressed in solid tumors [123].
Resistance against serpin B9 was also observed for a mutant granzyme B (R201K) [124]. The same
mutant was also used with an epidermal growth factor receptor-specific scFv antibody [34]. In another
immunotoxin granzyme B was fused to the humanized anti-Her2/neu scFv antibody 4D5 and for
further enhancement, a fusogenic peptide (called 26) was introduced [125]. Treatment with nanomolar
concentrations of GrB/4D5/26 resulted in specific cytotoxicity, induction of apoptosis, and efficient
downregulation of signal pathways. Even tumor cells that are resistant to the tyrosine kinase inhibitor
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lapatinib or the antibody trastuzumab, and cells resistant to chemotherapeutic agents showed no
cross-resistance to the GrB-based fusion proteins [125].
Ricin is a plant ribosome-inactivating protein consisting of a cell-binding B chain and a catalytic
A chain. Following endocytosis, ricin is transported in vesicular carriers to the endoplasmic reticulum
where the two chains are separated reductively. The A chain embeds in the membrane of the
endoplasmic reticulum and then retrotranslocates across this membrane [126]. Although the B chain
appears to be not involved in the cytosolic translocation, it has been shown that the presence of
the B chain enhances the effect of A chain-based immunotoxins. Highly purified preparations of
the two chains were separately coupled to anti-human immunoglobulin antibodies and mixtures of
the resulting immunotoxins markedly synergized in vitro in their ability to kill target cells [127]. In
contrast, A chain and B chain-containing immunotoxins of irrelevant specificity did not synergize with
the specific immunotoxins indicating that the synergy is specific [127]. In vitro killing of target cells by
either univalent antibody fragments or divalent full antibodies of rabbit anti-human immunoglobulins
coupled to ricin A chain can be specifically potentiated by a piggyback treatment with ricin B chain
coupled to goat anti-rabbit immunoglobulins [128]. A bispecific monoclonal antibody recognizing
both CEA and RTA was tested for its ability to target the ricin A chain to CEA-expressing tumor cells
alone and in combination with the B chain [129]. The antibody induced significant cytotoxicity against
target cells using a ricin toxin A chain concentration below that known to be intrinsically cytotoxic.
The addition of the B chain then further enhanced the cytotoxicity of the bispecific antibody [129].
Table 6. Toxic proteins of eukaryotic origin that have been used in targeted toxins. The pore forming
proteins oligomerize in a Ca2+ dependent manner to form pores on the target cell. They in principle
fulfill both functions, the toxic effect and the ability to overcome the membrane barrier, in one molecule.
Granzymes are apoptosis inducing serine proteases that are supported by pore forming proteins to
enter the cells. An enhancement factor cannot be provided here since efficacy and enhancement are
inextricably linked with each other in these systems.
Enhancer = Toxin Antigenic Target Targeted Toxin Enhancer = ToxinConcentration (IC50)
Ref.
Perforin
(N-terminal 34 amino acids) CTLA-4 (CD152) hS83P34 200–1000 nM [119]
Perforin/Granzyme B VEGF VEGF-SEA (D227A mutant) released by attractedimmune cells [120]
Granzyme B
Lewis Y GzmB-dsFv-B3 35–140 nM [121]
CD64
Gb-H22(scFv) 1.7–17 nM [122]
Gb(R201K)-H22(scFv) 4–7 nM [124]
CD30 Gb(R201K)-Ki4(scFv) 1.7 nM [130]
EGFR Gb(R201K)-scFv1711 133 nM [34]
HER2
GrB/4D5 242–629 nM [125]
GrB/4D5/26 29–93 nM [125]
Granzyme M CD64 Gm-H22(scFv) 1.2–6.4 nM [123]
4.2. Secondary Metabolites
In addition to proteins and peptides of eukaryotic origin, some secondary plant metabolites show
a very promising potential to enhance the endosomal escape of targeted toxins. In particular some
glycosylated triterpenoids (saponins) of the oleanane type isolated from Gypsophila paniculata L. (baby’s
breath) and Saponaria officinalis L. (common soapwort) have the ability to specifically augment the
cytotoxicity of several ribosome-inactivating proteins [131–133]. This augmentation is neither due to
a permeabilization of the plasma membrane—it occurs at non-permeabilizing concentrations of the
glycosylated triterpenoid—nor due to an increase of the rate of endocytic events, but rather due to
the mediation of an enhanced endosomal escape [134,135]. Findings hinted at an interaction of the
Toxins 2016, 8, 200 15 of 28
toxins with the saponins at acidic pH as it is found in late endosomes and the lysosome (pH ~5) [136].
Further, the acidic environment is even a prerequisite for the synergistic action since inhibition of
vesicle acidification by bafilomycin A or chloroquine restored the survival of the tested cells [137].
It is postulated that the protonation of the glucuronic acid, which is present in this particular group of
saponins, and interaction with endosomal cholesterol may play an important role [137,138]. Targeted
toxins can become enhanced in their cell killing efficacy by these saponins dependent on cell line and
amount of target receptor expression by 3000-fold up to 4,000,000-fold [101,139–141], which resulted
in a broadening of the therapeutic window in mice between 10-fold and 500-fold. After injection of the
targeted toxins, a substantial reduction in the tumor volume occurred and complete remissions were
seen in many cases of different tumor models [142–144]. The tumor regression across all these studies
was in average about 90% and the required dose was only 2% of the dose used for a treatment without
saponins. The lower dose resulted in decreased side effects and reduced immunogenicity.
SO1861 from Saponaria officinalis L. and SA1641 from Saponinum album (a saponin composite
from Gypsophila spec.) are two of the few saponins that were found to display such tremendous
synergism with several type I RIPs, such as saporin [101,133], dianthin [101,145] or agrostin [132]. In
contrast, the cytotoxicity of the A chain from the type II RIP ricin was only enhanced 16-fold [101]
and the cytotoxicity of the bacterial Pseudomonas exotoxin A remained unaffected by the combinatory
treatment [101,137].
5. Synthetic Peptide Enhancers
As described before, there are a number of peptides of viral, bacterial and eukaryotic origin that
have been successfully used to enhance the cytotoxicity of targeted toxins. Additionally, peptides have
been synthetically produced and evaluated for their potentiating effects.
A main group of synthetic peptides that showed significant increase in protein delivery are
polyarginines. Peptides consisting of a different number of sequential arginines increased the cytosolic
delivery of proteins such as green fluorescent protein by modulating protein transport in the late
endosomes and lysosomes [146].
In the case of targeted toxins, a polyarginine synthetic peptide (Arg9) was fused to an
immunotoxin containing a truncated version of Pseudomonas exotoxin (PE35) and directed to the
carcinoembryonic antigen (CEA). The Arg9 peptide increased the cytotoxicity of PE35/CEA(Fv)/KDEL
markedly [147]. Another synthetic peptide called pJVE doubled the cytotoxic effects of the RIP dianthin
when it was delivered to cells as a fusion protein consisting of transferrin as targeting moiety, pJVE as
enhancer and dianthin as toxic moiety (Tfn-pJVEDIA). The pJVE peptide interacts with the endosomal
membranes and facilitates the release of targeted toxins into the cytosol [80].
6. Physicochemical Techniques
The endosomal entrapment of therapeutics can also be overcome by physicochemical techniques.
Such techniques do not rely on the usage of molecules that modulate the intracellular trafficking of
toxins by their own. Instead, they are based on the use of physical principles or chemical reactions
that directly trigger the intracellular drug delivery and may disrupt the endosomal or lysosomal
membranes. Some examples of these techniques are ultrasounds [148], magnetic nanoparticles [149]
and plasmonic nanobubbles [150]. Thus far, most of these techniques have only been utilized for
the delivery of therapeutics other than proteins such as nucleic acids or small chemotherapeutic
drugs. However, a technique called photochemical internalization has been extensively studied for the
delivery of targeted toxins.
Photochemical internalization is a strategy based on photodynamic therapy for the cytosolic
delivery of protein therapeutics that have been trapped during their intracellular trafficking inside
the endosomes and lysosomes [151,152]. The release of targeted toxins is triggered by a light-induced
photochemical reaction. When targeted toxins and a photosensitizer are administered to cells, both
compounds are internalized and accumulate in the endosomes and lysosomes. Then, cells are exposed
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to light and reactive oxygen species (mainly singlet oxygen 1O2) are produced by the photosensitizer.
The chemical reactions induced by singlet oxygen lead to the disruption of endosomal membranes [153].
Subsequently, targeted toxins are released into the cytosol and they reach their intracellular target. The
most common photosensitizers for photochemical internalization are disulfonated compounds based
on tetrapyrrole ring systems (porphins) [10,154,155].
This approach has been proven successful in enhancing the cytotoxicity of several targeted
toxins (Table 7). They were composed of either gelonin or saporin, and targeted to different cellular
receptors, including CD44 [156], CD133 [157,158], chondroitin sulfate proteoglycan 4 [159], EGFR [160],
epithelial cell adhesion molecule (EpCAM, EGP-2) [161,162], human epidermal growth factor receptor 2
(HER2) [163] and vascular endothelial growth factor receptor [164]. Photochemical internalization is
a minimally invasive strategy for light-controlled endosomal escape of targeted toxins that can be used
for many different kinds of cancer cells [10].
Table 7. Targeted toxins enhanced by photochemical internalization. The photochemical reaction of
a photosensitizer triggered by light exposure causes the disruption of endosomal membranes. This
results in the release of targeted toxins into the cytosol and increases their cytotoxicity.
Photosensitizer





AlPcS2a gelonin CSPG4 scFvMEL/rGel 5 µg/mL [159]
TPCS2a
gelonin
EGFR rGel/EGF 0.1–0.4 µg/mL [160]
HER2 MH3-B1/rGel 0.1–0.4 µg/mL [163,165]
VEGFR VEGF121/rGel 0.4 µg/mL [164]
saporin
CD133 CD133/1 (AC133)-saporin 0.4–1 µg/mL [157,158]
CD133 CD133/2 (293C)-saporin 0.2–1 µg/mL [157]
CD44 IM7-saporin 0.35–1 µg/mL [156]
EpCAM (EGP-2) 3–17I-saporin 0.35 µg/mL [162]
HER2 Trastuzumab-saporin 0.2 µg/mL [166]
TPPS2a
gelonin EpCAM (EGP-2) MOC31-gelonin 0.3–1 µg/mL [161]
saporin EGFR Cetuximab-saporin 0.1–1 µg/mL [167]
EGFR EGF-saporin 0.1–0.2 µg/mL [168]
7. Discussion
Surgery, radiotherapy and conventional chemotherapy are the most important means in the
treatment of cancer. While surgery is limited to accessible tumors and in most cases is not suitable
for metastasized cancer, radiotherapy and chemotherapy are accompanied by undesired side effects
and adequate efficacy is often missing due to formation of resistances. In the last decades targeted
tumor therapies that address more specific properties of tumor cells were developed; they mainly
comprise receptor tyrosine kinase inhibitors [169] and antibody-based therapies [2]. The cytotoxic
effect of antibodies can be mediated by direct effects of the antibody such as acting as receptor
antagonist or by inducing apoptosis, by indirect effects such as complement dependent cytotoxicity,
antibody-dependent cell-mediated cytotoxicity or modulation of T cell functions, and by specific
effects on the tumor environment in particular on vascularization [170]. To augment the effect
of antibodies, they were linked to cytotoxic substances, either small molecules or protein-based
toxins [171]. The antibodies can be replaced by other targeting ligands such as cytokines or growth
factors, which also results in targeted toxins [171]. Conjugates with small toxic molecules are more
advanced than immunoconjugates with protein-based toxins, but they still reveal problems with linker
chemistry, conjugate homogeneity and overall stability [172–174]. Moreover, the toxic substances in
antibody small drug conjugates are typically competitive inhibitors, whereas the protein toxins are
enzymes. Therefore, only a small number of these toxic proteins must enter the cytosol to mediate
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cell death [175]. Although protein-based targeted toxins appear to have unbeatable advantages
including high target-specific toxicity and recombinant production of homogenous molecules, no
antibody-targeted protein toxin for tumor therapeutic applications has been launched to date and
only one ligand-targeted fusion protein, denileukin diftitox, was approved by the U.S. Food and
Drug Administration [102]. As described in this review article, the low cytosolic uptake of the toxin
components is a major concern regarding therapy with targeted toxins. Reasons for this are poor
internalization, recycling to the cell surface and lysosomal degradation [6–8]. Thus, the advantage of
the high efficacy of the protein toxin is undermined by the necessity to apply high doses of the toxin
to gain the desired rate of cytosolic translocation. It is notable that denileukin diftitox that uses its
evolutionarily developed intrinsic endosomal escaper enhancer did not lead to a breakthrough in the
application of targeted toxins even 17 years after approval.
It is therefore obvious that efficacy enhancers are important tools to improve the endosomal
escape rate and accordingly decrease the dosage. All the efficacy enhancers presented here (Figure 1),
independent of their origin and structure, show substantial enhancer effects, however, none of them is
tumor target specific by itself; they all depend on the specificity of the targeted toxin. In the case of
off-target effects of the toxin, these unwanted effects might also be enhanced and result in increased
side effects. This can be the case due to lack of antibody specificity resulting from the presence of the
target receptor on healthy tissue (target dependent toxicity) or due to targeted toxin binding to other
cell surface components rather than specifically to its target receptor (target independent toxicity) [176].
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Figure 1. Endoso al escape enhancers for targeted toxins: (A) as native bacterial toxins, targeted
toxins also bind to the target receptor and are internalized; (B) embrane-destabilizing agents
and photosensitizers typically enter cells by passive diffusion and accumulate preferably in
the endosomal membrane; (C) cell-penetrating peptides (CPPs), native bacterial translocation
do ains and pore-forming proteins directly mediate the entry of the toxins into the cytosol;
(D) membrane-destabilizing agents and photosensitizers rather destroy the membrane integrity
resulting in leaky endosomes, which allows translocation of the toxins; and (E) the toxins affect
vital metabolic athways in the cytosol finally resulting in apoptosis of the cell.
Another problem with enhancer substances concerns pharmacokinetic issues. In most cases, the
enhancer substance is applied independently from the drug and has its own behavior in liberation,
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absorption, distribution, metabolization and excretion. Since both compounds, the enhancer and the
targeted toxin, must be at the site of interaction at the same time, a careful synchronization of both
kinetics is required. Moreover, chemical enhancers, secondary metabolites and photosensitizers are
non-specifically taken up by off-target cells. All these facets make it very difficult to determine the
mutual dose dependency of both substances, the spatial and temporal distance of both applications,
and the therapeutic window.
There are mainly two solutions for the mentioned problems, first, to also target the enhancer
molecules to the tumor cells, but independently of the targeted toxin, and second, to combine enhancer
and targeted toxin in a single drug molecule. Neither solution can solve both problems discussed
before. The first solution avoids off-target uptake of the enhancer and therefore minimizes undesired
enhancement of misguided targeted toxins to regular cells but cannot ensure synchronization while
the second solution results in synchronization of the kinetics but will still enhance the cytotoxic effect
if the antibody binds and is internalized by an off-target cell.
Cell penetrating peptides can be fused to the toxin moiety to make them target cell
specific [80,83,84]. The idea is to inactivate the penetrating property until the antibody has been
bound to the target receptor and internalized. A possible solution is to place the CPP between
targeting moiety and toxin and include an endosomal cleavable peptide that leads to the release of
the targeting moiety inside the endosomes, which in turn results in exhibition of the CPP [83,84].
Chemical enhancers and secondary metabolites can be encapsulated into targeted nanocarriers;
a pH-sensitive endosomal stimulus can then result in controlled release [177,178]. The nanocarriers
can be in addition spiked with the targeted toxins or applied independently, each variant associated
with the pros and cons discussed before. Further specificity might be achieved by use or design of
toxins that are predominantly activated only in tumor cells as described for apoptin [179,180]. In the
case of photochemical internalization, nothing happens even in the case of colocalization of drug and
enhancer in off-target cells. Light exposure then results in disruption of the endosomal membrane.
Additional specificity is thus being obtained by only illuminating the site of the tumor [151]. This is
however achieved at the expense of completeness in the treatment of metastases since unidentified
micrometastases cannot be embraced by this system except for unenhanced targeting. This problem
might be solved by targeted bioluminescence, however, firefly luciferase bioluminescence does not
generate sufficient photons to induce photodynamic toxicity [181].
The use of enhancers leads to a further general problem, the immunogenicity of drugs. In
particular, peptide- and protein-based enhancers can contain immunogenic epitopes, and small
molecule enhancers, even if not immunogenic by themselves, might boost a possible immune response
against the targeted toxin. Strategies to deimmunize enhancers might be applied in the same way as
described for targeted toxins [96]. Wherever possible, human protein sequences should be used as
exemplified by humanized antibodies or human toxins such as angiogenin or granzymes.
8. Conclusions
Antibody targeted delivery of protein toxins to tumor cells is one of the most promising ideas in
the fight against cancer, however, the fact that decades of research have not resulted in any approved
antibody-targeted protein toxin for tumor therapy shows that cytosolic protein delivery is a formidable
challenge. The main barrier is the endosomal membrane that prevents release of the toxin before
degradation or recycling. To overcome this obstacle, a number of strategies were developed that
can be summarized as endosomal escape enhancers. The nature of these enhancers is multifarious
including chemical substances, cell-penetrating peptides, protein domains, secondary metabolites, and
light-sensitive substances. Until now, it is not finally solved how spatio-temporal synchronization of
enhancer and drug should be accomplished, and how enhancement of drugs that were misdirected
into regular cells should be prevented. Further ideas are definitely required to solve the conflict
between linked enhancer/drug delivery and independently targeted enhancers. This might include
new controlled delivery techniques and novel tumor activated toxins.
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